NCT00577278View on ClinicalTrials.gov

A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 3, 2007

Primary Completion Date

May 30, 2019

Study Completion Date

December 14, 2023

Conditions
Graft Versus Host DiseaseLeukemiaLymphoma
Interventions
BIOLOGICAL

rituximab

Given IV

DRUG

fludarabine phosphate

Given IV

DRUG

melphalan

Given IV

DRUG

sirolimus

Given PO

DRUG

tacrolimus

Given PO or IV

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Undergo APBSCT

RADIATION

indium In 111 ibritumomab tiuxetan

Given IV

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Given IV

OTHER

laboratory biomarker analysis

Correlative Studies

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00577278 - A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | Biotech Hunter | Biotech Hunter